Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Find Your Distributors

Select Your Country or Region

 $ USD

Product Inquiry: sales@probechem.com
Order/PO receiving: order@probechem.com

You are here:Home-Chemical Inhibitors & Agonists-Cell Cycle/DNA Damage-ATM/ATR-BAY-1895344
BAY-1895344

Chemical Structure : BAY-1895344

CAS No.: 1876467-74-1

Add to Favorites

BAY-1895344 (Elimusertib, BAY1895344)

Catalog No.: PC-60277Not For Human Use, Lab Use Only.

BAY 1895344 (BAY1895344, Elimusertib) is a novel potent, highly selective ATR kinase inhibitor with IC50 of 7.0 nM.

Packing Price Stock Quantity
5 mg $88 In stock
10 mg $128 In stock
25 mg $198 In stock
50 mg $328 In stock
100 mg Get quote
Get Quotation Now
* Please select Quantity before adding items.
 or Bulk Inquiry

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

BAY 1895344 (BAY1895344, Elimusertib) is a novel potent, highly selective ATR kinase inhibitor with IC50 of 7.0 nM.
BAY 1895344 (Elimusertib) demonstrated high selectivity in an in-house kinase selectivity panel (with exception mTOR IC50=35 nM) and KINOMEscan profiling.
BAY 1895344 inhibited hydroxyurea-induced ATR-dependent H2AX phosphorylation with IC50 of 36 nM in HT-29 cells.
BAY 1895344 inhibits proliferation in a broad spectrum of human cancer cell lines ( Lymphoma cells IC50=9-32 nM).
BAY 1895344 shows strong antitumor efficacy as monotherapy in CDX models, as well as synergistic activity in combination with chemotherapy or EBRT.

Physicochemical Properties

M.Wt 375.436
Formula C20H21N7O
Appearance Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO
Chemical Name/SMILES

(R)-3-methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl)morpholine

References

1. Lücking U, et al. J Med Chem. 2020 Jul 9;63(13):7293-7325.
2. Wengner AM, et al. Mol Cancer Ther. 2020 Jan;19(1):26-38.
3. Yap TA, et al. Cancer Discov. 2021 Jan;11(1):80-91.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: